EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aprinoia Therapeutics's Enterprise Value is $0.00 Mil.
Aprinoia Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-14.14 Mil. Therefore, Aprinoia Therapeutics's EV-to-FCF for today is 0.00.
The historical rank and industry rank for Aprinoia Therapeutics's EV-to-FCF or its related term are showing as below:
APRI's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 6.305 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Aprinoia Therapeutics EV-to-FCF Chart
Aprinoia Therapeutics Annual Data
Trend
Dec21
Dec22
EV-to-FCF
-
-
Aprinoia Therapeutics Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
EV-to-FCF
-
-
-
-
Competitive Comparison of Aprinoia Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Aprinoia Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprinoia Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Aprinoia Therapeutics's EV-to-FCF falls into.
Aprinoia Therapeutics's current Enterprise Value is $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprinoia Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-14.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aprinoia Therapeutics's PE Ratio for today is calculated as:
Aprinoia Therapeutics's share price for today is $0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aprinoia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aprinoia Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Aprinoia Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APRI has been successfully added to your